Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Rev Med Interne ; 41(4): 284-288, 2020 Apr.
Artigo em Francês | MEDLINE | ID: mdl-31983550

RESUMO

INTRODUCTION: Immune Checkpoint Inhibitor (ICI) therapy is now a standard of care in numerous cancers with very promising results. Nevertheless, adverse events, and especially immune-related adverse events (irAEs) not reported during clinical trials, are emerging and can be life-threatening. OBSERVATION: We report here a teachable case of a 80 year-old man, of third-degree atrioventricular block consecutive to myocarditis associated with the administration of nivolumab (anti-PD1) monotherapy. CONCLUSION: Myocarditis occurring during ICI treatment is a rare but potentially lethal event. Daily serum troponin level seems to predict ICI-related myocarditis but interpretation could be difficult in the context of associated myositis. Echocardiography and cardiac MRI are also useful but can remain negative. Electrocardiogram is a cornerstone of myocarditis diagnosis. In case of cardiac involvement, continuous heart rhythm monitoring should be performed in addition to the administration of high-dose corticosteroids therapy and the cessation of ICI therapy. Add-on treatments should be discussed with a well-trained multidisciplinary team.


Assuntos
Bloqueio Atrioventricular/induzido quimicamente , Inibidores de Checkpoint Imunológico/efeitos adversos , Miocardite/induzido quimicamente , Nivolumabe/efeitos adversos , Idoso de 80 Anos ou mais , Antineoplásicos Imunológicos/efeitos adversos , Antineoplásicos Imunológicos/uso terapêutico , Bloqueio Atrioventricular/complicações , Bloqueio Atrioventricular/patologia , Carcinoma de Células Escamosas/complicações , Carcinoma de Células Escamosas/tratamento farmacológico , Diabetes Mellitus Tipo 2/complicações , Humanos , Inibidores de Checkpoint Imunológico/uso terapêutico , Imunoterapia/efeitos adversos , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares/tratamento farmacológico , Masculino , Miocardite/complicações , Miocardite/patologia , Nivolumabe/uso terapêutico , Receptor de Morte Celular Programada 1/antagonistas & inibidores , Receptor de Morte Celular Programada 1/imunologia
2.
Rev Mal Respir ; 34(9): 976-990, 2017 Nov.
Artigo em Francês | MEDLINE | ID: mdl-29150179

RESUMO

BACKGROUND: The aim of ESCAP-2011-CPHG, promoted by the French College of General Hospital Respiratory Physicians, was to describe therapeutic strategies in lung cancer in the first 2 years after diagnosis, in a real-life setting. This article focuses on patients undergoing surgical management of a non-small cell lung cancer (NSCLC). METHODS: A prospective multicentre study was conducted in 53 French general hospitals. For each patient with lung cancer diagnosed in 2010, a standardised form was completed following each change in treatment strategy up to 2 years after diagnosis. RESULTS: Overall, 3418 of the 3943 included patients had NSCLC. 741 patients (21.7%) underwent curative surgery (stage 0-II, IIIA, IIIB, and IV: 65%, 27%, 3% and 5%, respectively). The therapeutic strategy changed less often in surgical than non-surgical patients and average follow-up time was longer: 23.3 months (SD: 9.3) versus 10.4 months (SD: 9.5) for non-surgical patients. Among patients with a surgical first strategy (92.6% of surgical patients as a whole), 56.9% did not receive any other treatment, 34.7% received chemotherapy, 5.9% radio-chemotherapy, 2.6% radiotherapy. At the end of follow-up, 55.8% were still alive without any other strategy, 13.1% had died, and 31.1% had received at least one more strategy. Among patients with a surgical second strategy, 63% had received chemotherapy alone during the first strategy. CONCLUSIONS: ESCAP -2011- CPHG assessed everyday professional practice in the surgical management of NSCLC in general hospitals. It pointed out the discrepancies between current guidelines and the therapeutic strategies applied in real life conditions.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/cirurgia , Carcinoma Pulmonar de Células não Pequenas/terapia , Neoplasias Pulmonares/cirurgia , Neoplasias Pulmonares/terapia , Padrões de Prática Médica , Pneumologia/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Pulmonar de Células não Pequenas/diagnóstico , Carcinoma Pulmonar de Células não Pequenas/epidemiologia , Estudos de Coortes , Feminino , Seguimentos , França/epidemiologia , Hospitais Gerais/organização & administração , Hospitais Gerais/estatística & dados numéricos , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/epidemiologia , Masculino , Pessoa de Meia-Idade , Pneumonectomia/métodos , Pneumonectomia/estatística & dados numéricos , Padrões de Prática Médica/estatística & dados numéricos , Pneumologia/organização & administração , Sociedades Médicas/organização & administração , Sociedades Médicas/normas , Recursos Humanos
3.
Rev Pneumol Clin ; 59(3): 161-5, 2003 Jun.
Artigo em Francês | MEDLINE | ID: mdl-13130203

RESUMO

Gastrointestinal metastasis from lung cancer is exceptional and generally asymptomatic. Other secondary localizations are often present. Metastastic dissemination may involve any portion of the gastrointestinal tract. Clinical expression is variable: dysphagia, anemia, bowel obstruction, peritonitis. Surgical treatment may be indicated in selected patients. We describe the cases of two patients who developed obstruction of the small bowel due to metastases from squamous-cell lung cancer. Bowel obstruction was in the inaugural sign in the first patient. Mesenteric metastasis was associated in the second patient.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/secundário , Carcinoma de Células Escamosas/secundário , Neoplasias Intestinais/secundário , Obstrução Intestinal/etiologia , Neoplasias Pulmonares/patologia , Carcinoma Pulmonar de Células não Pequenas/complicações , Carcinoma de Células Escamosas/complicações , Humanos , Neoplasias Intestinais/complicações , Masculino , Pessoa de Meia-Idade
4.
Presse Med ; 32(22): 1028-30, 2003 Jun 21.
Artigo em Francês | MEDLINE | ID: mdl-12876519

RESUMO

INTRODUCTION: Vibrio vulnificus proliferates during the summer in salt water where it infects the crustaceans. Expression of its pathogenicity depends on the underlying condition and mode of contamination. OBSERVATION: A 65 year-old man presented with a Vibrio vulnificus septicaemia of cutaneous origin, transmitted when he cut himself with a crawfish. The severity of the infection was enhanced by severe immuno-depression and haemochromatosis. The infection regressed with appropriate antibiotherapy. COMMENTS: Severe V. vulnificus infections are rare. Depending on the underlying condition and mode of contamination, one can distinguish between benign gastro-enteritis, local occasionally devastating infections and usually fatal septicaemia. CONCLUSION: Even the most severe forms of V. vulnificus infections may be cured with early and well adapted anti-infectious treatment.


Assuntos
Decápodes , Lacerações/complicações , Sepse/etiologia , Vibrioses/etiologia , Vibrio vulnificus/patogenicidade , Idoso , Antibacterianos/uso terapêutico , Humanos , Lacerações/microbiologia , Masculino , Sepse/tratamento farmacológico , Sepse/patologia , Índice de Gravidade de Doença , Vibrioses/tratamento farmacológico , Vibrioses/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...